With a pipeline that activates tumor-fighting immune cells, Synthorx is looking to raise $100 million through an initial public offering.
The San Diego company filed the paperwork Nov. 13, seeking to list on the Nasdaq under the symbol “THOR.” Synthorx’s focus is cancer therapies.
“Our proprietary, first-of-its kind platform technology expands the genetic code by adding a new DNA base pair and is designed to create optimized biologics, which we refer to as synthorins,” states the U.S. Securities and Exchange Commission filing.
“Based on our preclinical studies, we believe our platform technology can generate a pipeline of additional therapeutics that are differentiated compared to drugs that have been engineered by other means.”
In April, Synthorx raised $63 million in a Series C round. The company’s lead drug candidate is called thor-707.
Plans call for thor-707 to undergo a phase 1/2 clinical trial in multiple tumor types. But first the company must file a new drug application, expected in the second quarter of 2019.
The company as of September had 24 full-time employees, according to the paperwork.